Pentoxifylline as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia; A New Perspective of an Old Drug
- Conditions
- Pentoxifylline as an Adjunct Therapy in the Treatment of Pneumonia
- Interventions
- Registration Number
- NCT06265389
- Lead Sponsor
- Tanta University
- Brief Summary
Pentoxifylline is a xanthine-derived, commercially produced drug approved for the management of intermittent claudication in patients suffering from a chronic occlusive arterial disease of the limbs. Pentoxifylline has been documented to display anti-inflammatory and immunomodulatory effects, as well as some antithrombotic and antiviral effects. This drug has also been shown to reduce lung fibrosis in patients with COVID-19, as well as to prevent thromboembolic events. This work aims to assess the benefit of oral Pentoxifyllin supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community-acquired pneumonia
- Detailed Description
This is a randomized clinical trial study that will be carried out on 100 children with Community-acquired pneumonia admitted to the Pulmonology Unit, Pediatric department.
Group 1: Pentoxifylline group, and group 2: Control group
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 100
- All children aged 2 months -18 years with community-acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x-ray indicating community-acquired pneumonia
- Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorders impacting respiration i.e. genetic, metabolic, neuromuscular disorders, and children with CHD affecting the pulmonary blood flow.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form Pentoxifylline Oral Tablet 50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form at a dose of 20 mg/kg/day, as an adjunct therapy to the usual pneumonia treatment for 5 days
- Primary Outcome Measures
Name Time Method Temperature 3 days Duration of defeverness
D-dimer 5 days Duration of normalization of D-dimer
Interleukin 6 5 days Duration of normalization of IL-6
Oxygen saturation 3 days Duration of normalization of hypoxia
Respiratory distress 3 days Duration of improvement of respiratory distress
CRP 5 days Duration of normalization of CRP
LDH 5 days Duration of normalization of LDH
- Secondary Outcome Measures
Name Time Method Pneumonia complications 14 days Occurrence of pneumonia complications
Hospital stays 14 days Duration of stay in hospital